Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Find value-oriented index funds that maintain low fees in 2024. Understand how value funds can enhance long-term retirement portfolios.
24,728 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Discover how nyxoah (nyxh) 2025 earnings could shape an investor's view of MedTech plays. This forward-looking analys...
Lane Generational just disclosed a sizeable stake in Evolv Technologies, signaling potential interest from big invest...
With summer on the horizon, energy markets react to travel demand and geopolitics. This guide highlights three energy...
When MoonLake Immunotherapeutics announced a larger-than-expected secondary offering, the stock wilted. This guide br...
Investors chasing income are eyeing three high-yield dividend stocks flashing warning signs as coverage tightens and ...
A respected investment firm recently disclosed a new stake in Portland General Electric, adding a signal to watch for...
A new humanoid robot from a major player has people talking. This article breaks down what a rival with a familiar lo...
A 2026 market shift is pushing workers away from chasing dozens of side gigs toward a lean, skill-driven playbook. Th...
JPMorgan Chase often commands a higher price tag than peers. This guide breaks down why that happens, what it means f...
A Live Oak Bancshares director sold 8,400 shares for about $336,000. Learn what this kind of insider action can signa...
A big shift in Berkshire’s thinking could put Alphabet in the spotlight for investors. This deep dive explains what t...